Search results
Showing results for
This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.
Chris Paton
BMBS BMedSci MBA DPhil FBCS Chris Paton - Honorary Visiting Scientist
Evelyne Kestelyn
Evelyne Kestelyn - Head of the Clinical Trials Unit
Ashata Dahal
Ashata Dahal - Public Engagement Manager (OUCRU Nepal)/ DPhil candidate (University of Oxford)
Suchita Shrestha
Suchita Shrestha - Head of the Clinical Trials Unit, OUCRU Nepal
Gisela Robles Aguilar
Gisela Robles Aguilar - Global Burden of Disease Researcher
Rachel Hounsell
Rachel Hounsell - Senior Researcher and Teaching Fellow
Proochista Ariana
- MSc IHTM Executive Team
- MSc IHTM Lecturers
- MSc IHTM advisory committee
- MSc MGH Lecturers
- Principal Investigators
- Research Scientists
Proochista Ariana - Associate Professor
Wirichada Pan-ngum
Wirichada Pan-ngum - Associate Professor
Kevin Marsh
Kevin Marsh - Professor of Tropical Medicine